Area of research
Physiology · Immunology and Allergy
Research interest
Research focused on Asthma and COPD, with related work in Health care, Indacaterol, Clinical decision making. Notable publications include 'Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs', 'Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD', and 'SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial'.
Assessing severity of anaphylaxis: a data-driven comparison of 23 instruments
Pilot study of mobile phone technology in allergic rhinitis in European countries: the <scp>MASK</scp>‐rhinitis study
Work productivity in rhinitis using cell phones: The <scp>MASK</scp> pilot study
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
Integrated care pathways for airway diseases (AIRWAYS-ICPs)
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients
Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale
Once-daily tiotropium Respimat (R) as add-on to at least medium- to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status
Data Archiving and Networked Services (DANS) 2014cited by 2position: first
Tiotropium Respimat Inhaler and the Risk of Death in COPD
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use